Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common tactic of adding in chimeric antigen receptors.
The company was formed to develop technology from scientific founder Dario Campana, and has been incubating in Johnson & Johnson’s South San Francisco JLABS site since 2015, with undisclosed funding from SR One, New Enterprise Associates and Novo Ventures.
Last month, Paul Hastings joined as president and CEO. Hastings was previously chairman, president and CEO of cancer company OncoMed Pharmaceuticals Inc.
Campana is professor of pediatrics and director of the Division of Immunopathology and Cell Therapy at the National University of Singapore. He’s also a founder of T cell therapy company Unum Therapeutics Inc.
Nkarta joins a field of at least nine other companies developing NK cell therapies as cytotoxic agents for cancer (see “NK Cells Across Generations”).
While Nkarta Inc. and two other companies have skipped to next-generation NK cell technologies, the majority of the competitors have first-generation products in the clinic. NK cell therapy companies initially went to the clinic with non-engineered versions of the innate immune cells, but many are now working on next-generation technologies. At least 10 companies have disclosed clinical or preclinical NK cell programs. Among